146 related articles for article (PubMed ID: 38937399)
1. Subcutaneous immunoglobulins (SCIG) for chronic inflammatory demyelinating polyneuropathy (CIDP): A comprehensive systematic review of clinical studies and meta-analysis.
Ramzi A; Maya S; Balousha N; Sabet H; Samir A; Roshdy MR; Aljarrah G; Saleh S; Kertam A; Serag I; Shiha MR
Neurol Sci; 2024 Jun; ():. PubMed ID: 38937399
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory effects of intravenous and subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: An observational study.
Svačina MKR; Meißner A; Schweitzer F; Ladwig A; Pitarokoili K; Kofler DM; Sprenger-Svačina A; Schneider C; Kohle F; Klein I; Wüstenberg H; Lehmann HC
Eur J Neurol; 2024 Jan; 31(1):e16079. PubMed ID: 37789648
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy.
Goyal NA; Karam C; Sheikh KA; Dimachkie MM
Muscle Nerve; 2021 Sep; 64(3):243-254. PubMed ID: 34260074
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: A Historical Perspective.
Cocito D; Peci E; Torrieri MC; Clerico M
J Clin Med; 2023 Nov; 12(22):. PubMed ID: 38002576
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy.
Markvardsen LH; Harbo T; Sindrup SH; Christiansen I; Andersen H; Jakobsen J;
Eur J Neurol; 2014 Dec; 21(12):1465-70. PubMed ID: 25041191
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.
van Schaik IN; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Praus M; Mielke O; Durn BL; Cornblath DR; Merkies ISJ;
Lancet Neurol; 2018 Jan; 17(1):35-46. PubMed ID: 29122523
[TBL] [Abstract][Full Text] [Related]
9. Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.
Vu T; Anthony N; Alsina R; Harvey B; Schleutker A; Farias J; Dang S; Suresh N; Gooch C
Muscle Nerve; 2021 Sep; 64(3):351-357. PubMed ID: 34076265
[TBL] [Abstract][Full Text] [Related]
10. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.
Cirillo G; Todisco V; Tedeschi G
Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of subcutaneous versus intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy: a real-life study.
Piscitelli E; Massa M; De Martino BM; Serio CS; Guglielmi G; Colacicco G; Tuccillo F; Habetswallner F
Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e115-e119. PubMed ID: 33122403
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years.
Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A
Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis.
Lazzaro C; Lopiano L; Cocito D
Neurol Sci; 2014 Jul; 35(7):1023-34. PubMed ID: 24469345
[TBL] [Abstract][Full Text] [Related]
14. Switch from intravenous to subcutaneous immunoglobulin IgPro20 in CIDP patients: a prospective observational study under real-world conditions.
Gingele S; Koch M; Saparilla AC; Körner GM; von Hörsten J; Gingele M; Seeliger T; Konen FF; Hümmert MW; Neyazi A; Stangel M; Skripuletz T
Ther Adv Neurol Disord; 2021; 14():17562864211009100. PubMed ID: 33948119
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study.
Hartung HP; Mallick R; Bril V; Lewis RA; Sobue G; Lawo JP; Mielke O; Durn BL; Cornblath DR; Merkies ISJ; van Schaik IN;
Eur J Neurol; 2020 Jan; 27(1):196-203. PubMed ID: 31400231
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Neurophysiological Follow-Up of Chronic Inflammatory Demyelinating Polyneuropathy Patients Treated with Subcutaneous Immunoglobulins: A Real-Life Single Center Study.
Alonge P; Di Stefano V; Lupica A; Gangitano M; Torrente A; Pignolo A; Maggio B; Iacono S; Gentile F; Brighina F
Brain Sci; 2022 Dec; 13(1):. PubMed ID: 36671992
[TBL] [Abstract][Full Text] [Related]
17. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
Markvardsen LH; Christiansen I; Jakobsen J
Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs.
Markvardsen LH; Harbo T
J Neurol Sci; 2017 Jul; 378():19-25. PubMed ID: 28566163
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?
Allen JA; Gelinas DF; Freimer M; Runken MC; Wolfe GI
J Neurol Sci; 2020 Jan; 408():116497. PubMed ID: 31765922
[TBL] [Abstract][Full Text] [Related]
20. Quality of life in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin.
Ryltoft AK; Al-Zuhairy A; Sindrup SH; Andersen H; Markvardsen LK
Acta Neurol Scand; 2020 Dec; 142(6):637-640. PubMed ID: 33404110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
